Literature DB >> 22382559

Peripartum cardiomyopathy presenting with syncope due to Torsades de pointes: a case of long QT syndrome with a novel KCNH2 mutation.

Orie Nishimoto1, Morihiro Matsuda, Kei Nakamoto, Hirohiko Nishiyama, Kazuya Kuraoka, Kiyomi Taniyama, Ritsu Tamura, Wataru Shimizu, Toshiharu Kawamoto.   

Abstract

Peripartum cardiomyopathy (PPCM) is a cardiomyopathy of unknown cause that occurs in the peripartum period. We report a case of PPCM presenting with syncope 1 month after an uncomplicated delivery. Electrocardiography showed Torsades de pointes (TdP) and QT interval prolongation. Echocardiography showed left ventricular systolic dysfunction and endomyocardial biopsy showed myocyte degeneration and fibrosis. Administration of magnesium sulfate and temporary pacing eliminated recurrent TdP. Genetic analyses revealed that recurrent TdP occurred via electrolyte disturbance and cardiac failure due to PPCM on the basis of a novel mutation in KCNH2, a gene responsible for inherited type 2 long QT syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382559     DOI: 10.2169/internalmedicine.51.5943

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  Value of the neutrophil-to-lymphocyte ratio in predicting left ventricular recovery in patients with peripartum cardiomyopathy.

Authors:  Ufuk Gürkan; Haldun Akgöz; Şukru Aksoy; Özlem Can Gürkan; Altug Osken; Sennur Unal Dayi; Dilaver Oz; Recep Haci
Journal:  Wien Klin Wochenschr       Date:  2017-07-12       Impact factor: 1.704

2.  The prognostic value of positive T wave in lead aVR: A novel marker of adverse cardiac outcomes in peripartum cardiomyopathy.

Authors:  Firdevs Aysenur Ekizler; Serkan Cay; Habibe Kafes; Ozcan Ozeke; Firat Ozcan; Serkan Topaloglu; Ahmet Temizhan; Dursun Aras
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-01-17       Impact factor: 1.468

Review 3.  Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.

Authors:  Mark McCauley; Sharath Vallabhajosyula; Dawood Darbar
Journal:  Card Electrophysiol Clin       Date:  2016-03-22

4.  A novel marker of persistent left ventricular systolic dysfunction in patients with peripartum cardiomyopathy: monocyte count- to- HDL cholesterol ratio.

Authors:  Firdevs Aysenur Ekizler; Serkan Cay
Journal:  BMC Cardiovasc Disord       Date:  2019-05-15       Impact factor: 2.298

Review 5.  Genetics of Peripartum Cardiomyopathy: Current Knowledge, Future Directions and Clinical Implications.

Authors:  Timothy F Spracklen; Graham Chakafana; Peter J Schwartz; Maria-Christina Kotta; Gasnat Shaboodien; Ntobeko A B Ntusi; Karen Sliwa
Journal:  Genes (Basel)       Date:  2021-01-15       Impact factor: 4.096

Review 6.  Peripartum cardiomyopathy: a global effort to find the cause and cure for the rare and little understood disease.

Authors:  Amy Li; K Campbell; S Lal; Y Ge; A Keogh; P S Macdonald; P Lau; John Lai; W A Linke; J Van der Velden; A Field; B Martinac; M Grosser; Cristobal Dos Remedios
Journal:  Biophys Rev       Date:  2022-01-24

Review 7.  Peripartum cardiomyopathy: current state of knowledge, new developments and future directions.

Authors:  Murat Biteker; Kadir Kayatas; Dursun Duman; Muhsin Turkmen; Biykem Bozkurt
Journal:  Curr Cardiol Rev       Date:  2014-11

8.  Genetic and Phenotypic Characterization of Community Hospital Patients With QT Prolongation.

Authors:  Charlotte Gibbs; Jacob Thalamus; Kristian Tveten; Øyvind L Busk; Jan Hysing; Kristina H Haugaa; Øystein L Holla
Journal:  J Am Heart Assoc       Date:  2018-08-21       Impact factor: 5.501

9.  Fragmented QRS as a candidate marker for left ventricular nonrecovery in patients with peripartum cardiomyopathy.

Authors:  Bahar Tekin Tak; Serkan Cay; Firdevs Aysenur Ekizler; Elif Hande Ozcan Cetin; Hilal Erken Pamukcu; Habibe Kafes; Nedret Ulvan; Ozcan Ozeke; Firat Ozcan; Serkan Topaloglu; Dursun Aras
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-10-06       Impact factor: 1.468

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.